<code id='D75F6ED530'></code><style id='D75F6ED530'></style>
    • <acronym id='D75F6ED530'></acronym>
      <center id='D75F6ED530'><center id='D75F6ED530'><tfoot id='D75F6ED530'></tfoot></center><abbr id='D75F6ED530'><dir id='D75F6ED530'><tfoot id='D75F6ED530'></tfoot><noframes id='D75F6ED530'>

    • <optgroup id='D75F6ED530'><strike id='D75F6ED530'><sup id='D75F6ED530'></sup></strike><code id='D75F6ED530'></code></optgroup>
        1. <b id='D75F6ED530'><label id='D75F6ED530'><select id='D75F6ED530'><dt id='D75F6ED530'><span id='D75F6ED530'></span></dt></select></label></b><u id='D75F6ED530'></u>
          <i id='D75F6ED530'><strike id='D75F6ED530'><tt id='D75F6ED530'><pre id='D75F6ED530'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          knowledge

          author:knowledge    - browse:258
          Peter Marks. -- health coverage from STAT
          Peter Marks, Director of the Center for Biologics Evaluation and Research at the Food and Drug Administration. Susan Walsh-Pool/Getty Images

          Peter Marks wants drug developers to ask more stupid questions.

          It’s part of the top Food and Drug Administration official’s plan to reinvigorate gene therapy, a field that has struggled despite significant technological advances. Some companies are shelving programs or going out of business, even when they have promising data. 

          advertisement

          The problems are numerous: The diseases are often exceptionally rare, limiting the potential market. Manufacturing at commercial quality is complex and expensive. Proving a drug works can be difficult, because there may be too few patients to run a traditional randomized study. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus